Jazz Pharmaceuticals (JAZZ) Worth Watching: Stock Rises 8.7% – Tale of the Tape

Jazz Pharmaceuticals (JAZZ) was a big mover last session, as the company saw its shares rise by nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company, as the stock is now up nearly 31% over the past one-month time frame.

This biopharmaceutical company has seen 3 positive estimate revisions in the past 30 days and the Zacks Consensus Estimate has moved higher over the same time frame, suggesting that more solid trading could be ahead for Jazz Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent move higher can turn into more strength down the road.

Jazz Pharmaceuticals currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.

Some other Zacks Rank #1 biopharma stocks include Lannett Company Inc. (LCI), Santarus Inc. (SNTS) and Shire plc (SHPG).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>